Beijing SL Pharmaceutical Co., Ltd., a biopharmaceutical company, research, development, and production of genetic engineering and related drugs People's Republic of China and internationally. The company's finished formulations include temozolomide; arsenic trioxide; lenalidomide capsules; paclitaxel injection; docetaxel injection; thymopentin; vinorelbine tartrate injection; hydroxyl-camptothecine; nimustine hydrochloride; asparaginase; PEG L-asparaginase; calcium foliate; recombinant human basic fibroblast growth factor; liraglutide; insulin aspart 30; insulin aspart 50; insulin aspart; dispersible; ornidazole; voriconazole; adefovir dipivoxil; levofloxacin hydrochloride; azithromycin; ribavirin; tenofovir disoproxil fumarate; valacylovir hydrochloride; lysozyme; stavudine; tropisetron hydrochloride; granisetron hydrochloride; omeprazole; coenzyme complex; ginkgo biloba extract; simvastatin; telmisartan; naftopidil; nicergoline; zaleplon; cytidine disodium triphosphate; febuxostat; filgrastim; recombinant human interleukin-11; and recombinant human interleukin-2 products. The company was formerly known as Beijing BaiLuyuan Bio-Pharmaceutical Co., Ltd and changed its name to Beijing SL Pharmaceutical Co., Ltd. in 1998. Beijing SL Pharmaceutical Co., Ltd. was founded in 1994 and is headquartered in Beijing, the People's Republic of China.
Research context
Beijing SL Pharmaceutical Co., Ltd appears in PyInvesting’s Shenzhen Stock catalogue. The price history above describes this recorded instrument; it does not by itself identify a company’s business or establish a continuous investment return.
- Currency
- CNY
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
These are the latest stored catalogue classifications, not a historical classification snapshot. An issuer description, classification effective date or currency may be unavailable. Check the issuer’s own disclosures and the observation dates before using these fields for research.
Review backtest assumptions and evidence before treating a chart or stored history as a research result.
5 years, 6 months ago
Beijing SL Pharmaceutical Co., Ltd is currently in a long term downtrend where the price is trading 7.9% below its 200 day moving average.
From a valuation standpoint, the stock is 20.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 7.7.
Beijing SL Pharmaceutical Co., Ltd's total revenue sank by 32.7% to $305M since the same quarter in the previous year.
Its net income has increased by 754.8% to $106M since the same quarter in the previous year.
Finally, its free cash flow grew by 2498.8% to $130M since the same quarter in the previous year.
Based on the above factors, Beijing SL Pharmaceutical Co., Ltd gets an overall score of 3/5.